Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma
This study provides real-world evidence that support the effectiveness and safety of combined anti-PD-1 antibody, apatinib and temozolomide for treating advanced AM, demonstrating a considerable ORR and prolonged survival, as well as acceptable tolerability.
Authors
- Lu Si (ORCID: https://orcid.org/0000-0002-2123-9761)
- Bin Lian
- Bixia Tang
- Li Zhou (ORCID: https://orcid.org/0000-0001-5348-3681)
- Xinan Sheng
- Xiaoting Wei (ORCID: https://orcid.org/0000-0002-0612-8465)
- Lili Mao (ORCID: https://orcid.org/0000-0003-3236-352X)
- Jiaran Zhang (ORCID: https://orcid.org/0000-0003-1160-9770)
- Siming Li (ORCID: https://orcid.org/0000-0001-7077-0404)
- Junjie Gu
- Caili Li (ORCID: https://orcid.org/0000-0003-0967-6077)
- Xuan Wang (ORCID: https://orcid.org/0009-0008-0390-8141)
- Xieqiao Yan (ORCID: https://orcid.org/0000-0002-1781-3193)
- Zhihong Chi (ORCID: https://orcid.org/0000-0001-6257-6775)
- Jun Guo (ORCID: https://orcid.org/0000-0001-8573-5556)
- Huichun Tian
- Chuanliang Cui (ORCID: https://orcid.org/0000-0001-6455-0843)
Institutions
- Ministry of Education (ET)
Publication Details
- Journal
- Cancer Management and Research
- Published
- 2025-05-01
- DOI
- https://doi.org/10.2147/cmar.s520937
- Citations
- 1
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Beijing Xisike Clinical Oncology Research Foundation
- National Natural Science Foundation of China
- Beijing Municipal Administration of Hospitals
- National Key Research and Development Program of China